Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

USA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...